Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen
Standard
Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen. / Kempski, Jan; Huber, Samuel.
in: INNERE MED, Jahrgang 63, Nr. 10, 10.2022, S. 1022-1027.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen
AU - Kempski, Jan
AU - Huber, Samuel
N1 - © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
PY - 2022/10
Y1 - 2022/10
N2 - Inflammatory bowel diseases (IBD) are systemic diseases that mainly manifest in the gastrointestinal tract. Due to chronically impaired intestinal homeostasis, they often require permanent and in some cases systemic therapy. The exact causes of IBD are largely unknown. It is postulated that these complex diseases arise in genetically susceptible individuals through a misdirected immune response, promoted by barrier defects, environmental toxins, and the gut microbiome. In this regard, the importance of the microbiome and its pathogenic changes (dysbiosis) in the pathogenesis of IBD is increasingly coming into focus. This review article presents the current state of research on the role of the microbiome in the development of IBD. Therapeutic approaches aimed at correcting intestinal dysbiosis are also discussed.
AB - Inflammatory bowel diseases (IBD) are systemic diseases that mainly manifest in the gastrointestinal tract. Due to chronically impaired intestinal homeostasis, they often require permanent and in some cases systemic therapy. The exact causes of IBD are largely unknown. It is postulated that these complex diseases arise in genetically susceptible individuals through a misdirected immune response, promoted by barrier defects, environmental toxins, and the gut microbiome. In this regard, the importance of the microbiome and its pathogenic changes (dysbiosis) in the pathogenesis of IBD is increasingly coming into focus. This review article presents the current state of research on the role of the microbiome in the development of IBD. Therapeutic approaches aimed at correcting intestinal dysbiosis are also discussed.
KW - Dysbiosis/therapy
KW - Fecal Microbiota Transplantation
KW - Gastrointestinal Microbiome
KW - Humans
KW - Inflammatory Bowel Diseases/etiology
KW - Intestines
U2 - 10.1007/s00108-022-01396-8
DO - 10.1007/s00108-022-01396-8
M3 - SCORING: Review
C2 - 36044059
VL - 63
SP - 1022
EP - 1027
JO - INNERE MED
JF - INNERE MED
SN - 2731-7080
IS - 10
ER -